Interaction of TFAP2C with the estrogen receptor-α promoter is controlled by chromatin structure

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3672-3679

  Woodfield, George W ^a   Hitchler, Michael J ^a   Chen, Yizhen ^a   Domann, Frederick E ^a   Weigel, Ronald J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACTIN; DNA DIRECTED DNA POLYMERASE ALPHA; ESTROGEN RECEPTOR ALPHA; GENE PRODUCT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE; HISTONE H3; LYSINE; PROTEIN TFAP2A; PROTEIN TFAP2C; TRANSCRIPTION FACTOR AP 2; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; CONTROLLED STUDY; CPG ISLAND; DEACETYLATION; DNA METHYLATION; EPIGENETICS; FEMALE; GENE ACTIVATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; RECEPTOR GENE; TRANSCRIPTION REGULATION;

ACETYLATION; AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; DNA METHYLATION; ENZYME INHIBITORS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; HYDROXAMIC ACIDS; LYSINE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR AP-2;

EID: 66649084614     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2343     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-2442 (Pubitemid 36682823)
3. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
4. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 1980;45:349-353 (Pubitemid 10212203)
5. Jordan C, Wolf MF, Mirecki DM, Whiford DA, Welshons WV. Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. CRC Critical Reviews in Clin Lab Sci 1988;97-152.
6. Weigel RJ, deConinck EC. Transcriptional control of estrogen receptor in estrogen receptornegative breast carcinoma. Cancer Res 1993;53:3472-3474
7. Carmeci C, deConinck EC, Lawton T, Bloch DA, Weigel RJ. Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology. Am J Pathol 1997;150:1563-1570
8. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994;54:2552-2555 (Pubitemid 24173735)
9. Lapidus RG, Ferguson AT, Ottaviano YL, et al. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996;2:805-810
10. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 1995;55:2279-2283
11. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res 2001;61:7025-7029 (Pubitemid 32946489)
12. Jang ER, Lim SJ, Lee ES, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene 2004;23:1724-1736 (Pubitemid 38445164)
13. Alao JP, Lam EW, Ali S, et al. Histone deacetylase inhibitor trichostatin A represses estrogen receptor α-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 2004;10:8094-8104 (Pubitemid 39587551)
14. Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor a expression and is repressed by the Her-2/neu/ phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 2004;24:8681-8690 (Pubitemid 39245087)
15. Madureira PA, Varshochi R, Constantinidou D, et al. The Forkhead box M1 protein regulates the transcription of the estrogen receptor α in breast cancer cells. J Biol Chem 2006;281:25167-25176 (Pubitemid 44401903)
16. McPherson LA, Baichwal VR, Weigel RJ. Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci U S A 1997;94:4342-4347 (Pubitemid 27194243)
17. Schuur ER, McPherson LA, Yang GP, Weigel RJ. Genomic structure of the promoters of the human estrogen receptor-α gene show changes in chromatin structure induced by ap2γ. J Biol Chem 2001;276:15519-15526 (Pubitemid 37373448)
18. Woodfield GW, Horan AD, Chen Y, Weigel RJ. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res 2007;67:8439-8443 (Pubitemid 47437415)
19. Ghosh MG, Thompson DA, Weigel RJ. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res 2000;60:6367-6375
20. Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC. Anestrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 1992;90:77-86.
21. McPherson LA, Loktev AV, Weigel RJ. Tumor Suppressor Activity of AP2α Mediated through a Direct Interaction with p53. J Biol Chem 2002;277:45028-45033 (Pubitemid 36159102)
22. Hitchler MJ, Wikainapakul K, Yu L, Powers K, Attatippaholkun W, Domann FE. Epigenetic regulation of manganese superoxide dismutase expression in human breast cancer cells. Epigenetics 2006;1:163-171
23. Rose SL, Fitzgerald MP, White NO, et al. Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol 2006;102:319-324 (Pubitemid 44056261)
24. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-692 (Pubitemid 46273572)
25. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005;41:2381-2402 (Pubitemid 41540617)
26. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006;125:315-326
27. Orford K, Kharchenko P, Lai W, et al. Differential H3K4 methylation identifies developmentally poised hematopoietic genes. Dev Cell 2008;14:798-809.
28. Pasini D, Hansen KH, Christensen J, Agger K, Cloos PA, Helin K. Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and polycomb-repressive complex 2. Genes Dev 2008;22:1345-1355
29. Nightingale KP, O'Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet 2006;16:125-136 (Pubitemid 43376058)
30. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007;449:1073-1077 (Pubitemid 350014604)
31. Comb M, Goodman HM. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res 1990;18:3975-3982 (Pubitemid 20222936)
32. Hermann R, Doerfler W. Interference with protein binding at AP2 sites by sequence-specific methylation in the late E2A promoter of adenovirus type 2 DNA. FEBS Lett 1991;281:191-195
33. Huang Y, Peng J, Oberley LW, Domann FE. Transcriptional inhibition of manganese superoxide dismutase (SOD2) gene expression by DNA methylation of the 5′ CpG island. Free Radic Biol Med 1997;23:314-320 (Pubitemid 27276612)
34. Gee JM, Eloranta JJ, Ibbitt JC, et al. verexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol 2009;217:32-41.